<DOC>
	<DOCNO>NCT02938572</DOCNO>
	<brief_summary>Proof-of-Principle Trial Investigating Pharmacodynamics , Pharmacokinetics , Safety NNC0143-0406 Subjects Type 1 Diabetes Mellitus</brief_summary>
	<brief_title>A Randomised Proof-of-Principle Trial Investigating Pharmacodynamics , Pharmacokinetics , Safety NNC0143-0406 Subjects With Type 1 Diabetes Mellitus</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 1</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Insulin Aspart</mesh_term>
	<criteria>Male female age 18âˆ’55 year ( inclusive ) time sign informed consent Subjects diagnose ( clinically ) type 1 diabetes mellitus least 365 day prior day screen Treated continuous subcutaneous insulin infusion least 90 day prior day screen Known suspect hypersensitivity trial product ( ) relate product Males sexually active surgically sterilise ( vasectomy otherwise ) partner use highly effective contraception method , randomisation 90 day dose , double barrier contraception ( e.g . condom spermicide ) combination either oral ontraceptive , contraceptive patch , diaphragm intrauterine device , together physical barrier condom . Male subject must also agree refrain sperm donation randomisation 90 day last dosing Female pregnant , breastfeed intend become pregnant childbearing potential use adequate contraceptive method ( adequate contraceptive measure require local regulation practice ) ( adequate contraceptive measure define sterilisation , hormonal intrauterine device , oral contraceptive , condom spermicide sexual abstinence vasectomise partner )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>